Chris Sauer

Gheorghe Comanici, Eric Bieber, Mike Schaekermann et al. · amazon-science, baidu

In this report, we introduce the Gemini 2.X model family: Gemini 2.5 Pro and Gemini 2.5 Flash, as well as our earlier Gemini 2.0 Flash and Flash-Lite models. Gemini 2.5 Pro is our most capable model yet, achieving SoTA performance on frontier coding and reasoning benchmarks. In addition to its incredible coding and reasoning skills, Gemini 2.5 Pro is a thinking model that excels at multimodal understanding and it is now able to process up to 3 hours of video content. Its unique combination of long context, multimodal and reasoning capabilities can be combined to unlock new agentic workflows. Gemini 2.5 Flash provides excellent reasoning abilities at a fraction of the compute and latency requirements and Gemini 2.0 Flash and Flash-Lite provide high performance at low latency and cost. Taken together, the Gemini 2.X model generation spans the full Pareto frontier of model capability vs cost, allowing users to explore the boundaries of what is possible with complex agentic problem solving.

Chris Sauer, Jinghui Dong, Leo Celi et al.

Over the past decades, both critical care and cancer care have improved substantially. Due to increased cancer-specific survival, we hypothesized that both the number of cancer patients admitted to the ICU and overall survival have increased since the millennium change. MIMIC-III, a freely accessible critical care database of Beth Israel Deaconess Medical Center, Boston, USA was used to retrospectively study trends and outcomes of cancer patients admitted to the ICU between 2002 and 2011. Multiple logistic regression analysis was performed to adjust for confounders of 28-day and 1-year mortality. Out of 41,468 unique ICU admissions, 1,100 hemato-oncologic, 3,953 oncologic and 49 patients with both a hematological and solid malignancy were analyzed. Hematological patients had higher critical illness scores than non-cancer patients, while oncologic patients had similar APACHE-III and SOFA-scores compared to non-cancer patients. In the univariate analysis, cancer was strongly associated with mortality (OR= 2.74, 95%CI: 2.56, 2.94). Over the 10-year study period, 28-day mortality of cancer patients decreased by 30%. This trend persisted after adjustment for covariates, with cancer patients having significantly higher mortality (OR=2.63, 95%CI: 2.38, 2.88). Between 2002 and 2011, both the adjusted odds of 28-day mortality and the adjusted odds of 1-year mortality for cancer patients decreased by 6% (95%CI: 4%, 9%). Having cancer was the strongest single predictor of 1-year mortality in the multivariate model (OR=4.47, 95%CI: 4.11, 4.84).